NEW YORK (GenomeWeb News) – Saladax on Friday said that it has reached a distribution deal with Transmedic covering Saladax's MyCare oncology therapeutic dose management assays in Singapore and Hong Kong.
The MyCare assays include My5-FU, MyPaclitaxel, and MyDocetaxel products, which guide physicians in maintaining an optimal therapeutic range during the period of treatment, the Bethlehem, Penn.-based firm said.
Saladax recently said that it will begin offering the My5-FU assay as part of the MyCare portfolio after it regained rights to the assay from Myriad Genetics.
"We are pleased to have the opportunity to expand the distribution of our MyCare portfolio through this agreement with Transmedic, an experienced and well-respected commercialization partner that has a solid track record of effectively distributing innovative specialty medical products throughout Southeast Asia," Mark Myslinksi, senior vice president and COO of Saladax, said in a statement.
Based in Singapore, Transmedic distributes a range of life science products and medical devices.
Financial and other terms of the deal were not disclosed.